Immunome Inc (NASDAQ: IMNM) is a clinical-stage biopharma company developing antibody-based therapies targeting difficult-to-treat cancers and infectious diseases. Using its proprietary B cell discovery platform, the company is building a differentiated oncology pipeline. Immunome offers investors early-stage biotech exposure with platform-driven development optionality.
最新股票文章

平頭哥分拆上市分析:阿里巴巴AI芯片業務的結構性風險與估值框架
阿里巴巴旗下平頭哥半導體擬分拆獨立上市,摩根大通估值介於250億至620億美元。本文從業務依賴度、估值方法論、地緣政策風險及港股科技板塊估值溢價等維度,解構該交易的結構性風險與分析框架。
24 小時前


